Nu Skin Enterprises, Inc. (NUS) stock
NUSNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/3068% below fair value
$4.03+0.02 (+0.50%)
Close on Nov 13, 2026Market cap $196.17MP/E –Yield –
Nu Skin Enterprises r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $10.80M, down 16.9% from the year before. Over ten years it grew -6.0% a year on average. The highest annual figure on record is $30.10M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.80M | -16.9% |
| FY2024 | Dec 31, 2024 | $13.00M | -42.5% |
| FY2023 | Dec 31, 2023 | $22.60M | -3.0% |
| FY2022 | Dec 31, 2022 | $23.30M | -14.3% |
| FY2021 | Dec 31, 2021 | $27.20M | +16.7% |
| FY2020 | Dec 31, 2020 | $23.30M | -22.6% |
| FY2019 | Dec 31, 2019 | $30.10M | +30.9% |
| FY2018 | Dec 31, 2018 | $23.00M | +4.5% |
| FY2017 | Dec 31, 2017 | $22.00M | -9.5% |
| FY2016 | Dec 31, 2016 | $24.30M | +20.9% |
| FY2015 | Dec 31, 2015 | $20.10M | +6.3% |
| FY2014 | Dec 31, 2014 | $18.90M | +5.0% |
| FY2013 | Dec 31, 2013 | $18.00M | +20.8% |
| FY2012 | Dec 31, 2012 | $14.90M | +9.6% |
| FY2011 | Dec 31, 2011 | $13.60M | +9.7% |
| FY2010 | Dec 31, 2010 | $12.40M | +19.2% |
| FY2009 | Dec 31, 2009 | $10.40M | – |
See a number that looks wrong?